NOGO-A Neutralizing Immunoglobulins for the Treatment of Neurological Diseases

Abstract

The present invention relates to antibodies to NOGO, pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders.

1 .- 30 . (canceled) 
     
     
         31 . A humanized monoclonal antibody which binds to an neutralizes human NOGO, the antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:89 or SEQ ID NO:90, and a light chain variable region having an amino acid sequence of SEQ ID NO:23 or SEQ ID NO:25, or a variant thereof comprising an analog of a complementarity determining region (CDR) of said antibody, wherein said variant retains the binding specificity and neutralizing ability of the antibody from which it was derived. 
     
     
         32 . A monoclonal antibody according to claim  1 , comprising VH and VL regions selected from the following list: H24L16 (SEQ ID 86+SEQ ID 23), H22L16 (SEQ ID 88+SEQ ID 23), H23L16 (SEQ ID 89+SEQ ID 23), H20L18 (SEQ ID 86+SEQ ID 25), H22L18 (SEQ ID 88+SEQ ID 25), H23L18 (SEQ ID 89+SEQ ID 25), and H24L18 (SEQ ID 90+SEQ ID 25). 
     
     
         33 . A host cell co-transfected with first and second vectors encoding heavy and light chains, respectively, of an antibody according to claim  1 . 
     
     
         34 . A host cell transfected with a vector encoding heavy and light chains of an antibody according to claim  1 . 
     
     
         35 . A method of producing an antibody according to claim  1  or  2 , comprising the step of culturing a host cell according to claim  3  or  4 , and recovering the antibody thereby produced. 
     
     
         36 . An antibody according to claim  1  or  2  produced by the method of claim  5 . 
     
     
         37 . A pharmaceutical composition comprising an anti-NOGO antibody or functional fragment thereof according to claim  1 ,  2  or  6 , together with a pharmaceutically acceptable diluent or carrier. 
     
     
         38 . An antibody according to claim  1 ,  2 , or  6  for use in the treatment of prophylaxis of a human patient.